Table 3.
Multivariate analysis on prognosis factors by pathological types for thyroid cancer survival in Yantai during 2012 − 2022
| Subgroup | PTC | FTC | MTC | ATC |
|---|---|---|---|---|
| HR(95%CI) | HR(95%CI) | HR(95%CI) | HR(95%CI) | |
| 2017 − 2022 | 0.555(0.410–0.750) | – | – | – |
| Female | 1.193(0.896–1.590) | – | – | – |
| Rural | 1.017(0.759–1.363) | – | – | – |
| 45 − 64 years | 1.369(0.901–2.079) | 0.694(0.179–2.684) | – | – |
| ≥ 65 years | 1.670(1.053–2.650) | 3.100(0.834–11.520) | – | – |
| White-collar class | 0.990(0.417–2.349) | – | – | 0.408(0.046–3.618) |
| Blue-collar class | 0.624(0.311–1.249) | – | – | 0.554(0.184–1.673) |
| Other occupations | 0.678(0.333–1.379) | – | – | 0.506(0.125–1.022) |
| Isthmus | 2.824(1.889–4.220) | 3.037(1.845–10.430) | – | – |
| Multiple | 0.780(0.535–1.137) | 2.014(0.593–6.840) | – | – |
| > 3 cm | 2.924(2.070–4.132) | 1.833(1.495–3.955) | 2.226(0.594–8.336) | 4.539(2.049–5.207) |
| Lymph node metastasis | 2.234(1.475–3.384) | 2.168(1.678–8.274) | 3.603(2.411–9.587) | 4.083(2.233–11.058) |
| 115 − 500 IU/ml | 7.325(4.660–11.524) | 1.585(0.167–15.050) | – | 0.354(0.282–3.971) |
| > 500 IU/ml | 14.693(9.686–22.290) | 13.320(1.778–18.977) | – | 0.287(0.035–5.562) |
| II | 2.693(1.344–5.396) | 1.915(1.402–9.121) | 2.538(1.314–3.943) | – |
| III | 3.591(1.811–7.119) | 3.721(1.622–14.390) | 2.735(1.834–6.228) | – |
| IV | 3.487(1.399–8.693) | 4.505(1.460–15.520) | 4.762(3.755–8.270) | – |
| > 3 months | 2.596(1.958–3.441) | – | 1.779(1.621–3.087) | – |
FTC Follicular thyroid cancer, MTC Medullary thyroid cancer, ATC Anaplastic thyroid cancer
–According to the log-rank test, there was no statistically significant difference in OS